Comparative Pharmacology
Head-to-head clinical analysis: DORYX versus OXYTETRACYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORYX versus OXYTETRACYCLINE HYDROCHLORIDE.
DORYX vs OXYTETRACYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain.
Oxytetracycline binds reversibly to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
100 mg orally every 12 hours on day 1, then 100 mg orally every 24 hours. For severe infections: 100 mg orally every 12 hours.
250-500 mg orally every 6 hours or 1-2 g/day divided every 12 hours intravenously.
None Documented
None Documented
Terminal elimination half-life is 18-22 hours in healthy adults; prolonged to 21-36 hours in renal impairment; clinically relevant for once-daily dosing and monitoring for accumulation.
6-10 hours (prolonged to 48-100 hours in renal impairment; consider dose adjustment in CrCl <50 mL/min)
Renal (40-60% as unchanged drug via glomerular filtration), biliary/fecal (20-30% as active and inactive metabolites), incomplete excretion leads to enterohepatic recirculation.
Renal (60-70% unchanged by glomerular filtration); biliary/fecal (20-35%)
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic